Acute Heart Failure - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 73 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Acute Heart Failure - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Acute heart failure - Pipeline Review, H2 2014', provides an overview of the Acute heart failure's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute heart failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute heart failure and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute heart failure
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acute heart failure and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acute heart failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute heart failure pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute heart failure
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute heart failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Acute Heart Failure Overview 7
Therapeutics Development 8
Pipeline Products for Acute Heart Failure - Overview 8
Acute Heart Failure - Therapeutics under Development by Companies 9
Acute Heart Failure - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Acute Heart Failure - Products under Development by Companies 14
Acute Heart Failure - Companies Involved in Therapeutics Development 15
Amgen Inc. 15
Novartis AG 16
Bayer AG 17
Trevena, Inc. 18
PhaseBio Pharmaceuticals, Inc. 19
Angion Biomedica Corp. 20
Lee's Pharmaceutical Holdings Limited 21
Anexon, Inc. 22
Nyken BV 23
Capricor Therapeutics, Inc. 24
Acute Heart Failure - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
serelaxin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ularitide - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
omecamtiv mecarbil - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
cenderitide - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
istaroxime - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
TRV-027 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ANX-042 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BR-5489 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ANG-4011 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
NYK-1112 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
TRV-120023 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
PB-1046 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Acute Heart Failure - Recent Pipeline Updates 53
Acute Heart Failure - Dormant Projects 64
Acute Heart Failure - Discontinued Products 65
Acute Heart Failure - Product Development Milestones 66
Featured News & Press Releases 66
Aug 05, 2014: Trevena Granted Key U.S. Method of Use Patent for TRV027 66
Jul 28, 2014: Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 66
Jun 27, 2014: OHM Laboratories To Launch Valsartan Tablets 67
May 23, 2014: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure 67
May 19, 2014: Juventas Therapeutics Data Demonstrates Significant Structural, Clinically Meaningful Benefit in Patients with Advanced Heart Failure 68
May 19, 2014: Trevena Highlights Phase 2b-BLAST AHF Trial for TRV027 at the European Society of Cardiology Heart Failure 2014 Meeting 69
May 16, 2014: FDA issues Complete Response Letter for RLX030 for acute heart failure 69
Apr 09, 2014: Aastrom Reports Data and Safety Monitoring Board Recommendation to Continue ixCELL-DCM Clinical Trial 70
Mar 27, 2014: Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome 70
Mar 25, 2014: FDA Staff Says Novartis' Serelaxin Shouldn't Be Approved 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Tables
Number of Products under Development for Acute Heart Failure, H2 2014 8
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Acute Heart Failure - Pipeline by Amgen Inc., H2 2014 15
Acute Heart Failure - Pipeline by Novartis AG, H2 2014 16
Acute Heart Failure - Pipeline by Bayer AG, H2 2014 17
Acute Heart Failure - Pipeline by Trevena, Inc., H2 2014 18
Acute Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2014 19
Acute Heart Failure - Pipeline by Angion Biomedica Corp., H2 2014 20
Acute Heart Failure - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2014 21
Acute Heart Failure - Pipeline by Anexon, Inc., H2 2014 22
Acute Heart Failure - Pipeline by Nyken BV, H2 2014 23
Acute Heart Failure - Pipeline by Capricor Therapeutics, Inc., H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Acute Heart Failure Therapeutics - Recent Pipeline Updates, H2 2014 53
Acute Heart Failure - Dormant Projects, H2 2014 64
Acute Heart Failure - Discontinued Products, H2 2014 65